XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
General (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 21, 2017
Nov. 21, 2011
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
General (Textual)              
Common stock, par value     $ 0.001   $ 0.001   $ 0.001
Common stock shares issued 5.3681            
Interest rate     3.00%   3.00%    
License agreement terms         License agreement between the Company and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales.    
Total operating expenses     $ 128 $ 215 $ 353 $ 451 $ 631
Accumulated deficit     (10,291)   $ (10,291)   (9,689)
Merger description         (i) The effectiveness of a registration statement on Form S-4, including a proxy statement and prospectus, (ii) approval by the stockholders of the Company and shareholders of Wize, (iii) as of the earlier of the Effective Time or August 30, 2017, Wize shall have available cash and cash equivalents of at least NIS 1,000,000, (iv) the Company has no liabilities as of the Effective Time (including any indebtedness owed to Can-Fite), and (v) receipt by Wize an interim tax pre-ruling from the Israeli Tax Authority.    
Private Placement [Member]              
General (Textual)              
Common stock gross proceeds   $ 3,330          
Warrant [Member]              
General (Textual)              
Warrants issued to purchase common stock   1,267,315          
Maximum [Member]              
General (Textual)              
Payment for milestone         $ 500    
Minimum [Member]              
General (Textual)              
Payment for milestone         $ 25    
Eye-Fite Ltd [Member]              
General (Textual)              
Issuance of common stock to Can-Fite, shares   8,000,000          
Common stock, par value   $ 0.001          
Accrual clinical trials cost             $ 75
Percentage of sublicensing revenues             20.00%
Future additional payments percentage         2.50%    
Can-Fite [Member]              
General (Textual)              
Common stock shares issued   480,022          
Exercise price per share   $ 5.148          
Percentage of voting power   50.00%          
Interest rate   2.50%          
Warrants issued to purchase common stock   1,455,228          
Common stock converted to additional payment   646,776     480,022    
Common stock converted to additional payment, value         $ 2,471    
Ordinary shares held         446,827    
Percentage of issued and outstanding share capital         1.35%    
Accrual clinical trials cost             $ 100
Percentage of expenses         15.00%    
Deferred payments     $ 4,942   $ 4,942    
Maturity date description         Such letter expired on October 10, 2016 but was extended on November 14, 2016 by Can-Fite under the same terms and conditions in order to fund the Company's operations. Such letter shall expire on the earlier of (1) completion of signed reverse merger transaction as described in note 1a above, or (2) decision of OphthaliX to cease any action in relation to such merger, or (3) February 28, 2017.    
Warrants expiration date   Nov. 20, 2016          
Can-Fite [Member] | Private Placement [Member]              
General (Textual)              
Common stock shares issued   466,139          
Common stock value issued   $ 2,400          
Shares issued   97,112          
Ordinary shares received   714,922          
Gross proceeds   $ 500          
Can-Fite [Member] | Warrant [Member]              
General (Textual)              
Common stock converted to additional payment   281,625          
Warrants exercisable period   5 years          
Exercise price of the warrants   $ 7.74          
Investors [Member] | Warrant [Member]              
General (Textual)              
Common stock converted to additional payment   323,384          
Warrants exercisable period   5 years          
Exercise price of the warrants   $ 7.74          
2017 PIPE one (Member)              
General (Textual)              
Common stock shares issued 4.1781